A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
Clinical trial NCT05199051 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05199051
- Sponsor
- Centre Antoine Lacassagne
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-03
- Primary completion
- 2028-07-10
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.